Table 2 Residual moxidectin in injection sites one year after 0.5 mg/kg dose
From: Safety of an extended-release injectable moxidectin suspension formulation (ProHeart® 12) in dogs
Animal number | Sex | Dose administered (μg) | Residual moxidectin (μg) | Dose remaining in injection site (%) |
|---|---|---|---|---|
1 | M | 4000 | 4.4 | 0.109 |
2 | M | 5000 | 1227 | 24.5 |
3 | M | 5000 | 1445 | 28.9 |
4 | M | 5000 | 34.0 | 0.679 |
5 | F | 4000 | 1.8 | 0.045 |
6 | F | 4000 | 586 | 14.6 |
7 | F | 4000 | 842 | 21.0 |
8 | F | 4000 | 1506 | 37.6 |